StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

RVMDBullishAnalyst Target Updateanalyst
High materiality7/10

Revolution Medicines price target raised to $240 from $239 at Truist

Oct 7, 2026, 2:16 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

bullish

AI summary

What happened, with direct paths to the underlying reporting

Truist raises RVMD target to $240; posted price $201.65.

  • Truist raises RVMD target to $240; price $201.65

Key facts

  1. 01

    Target: $240

  2. 02

    Posted price: $201.65

  3. 03

    Analyst firm: Truist Financial

  4. 04

    Analyst: Gregory Renza

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.